Related Experiment Video
Updated: Apr 25, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
β-catenin contributes to lung tumor development induced by EGFR mutations
Sohei Nakayama1, Natasha Sng1, Julian Carretero2
1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Abstract:
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show that β-catenin is essential for development of EGFR-mutated lung cancers. β-Catenin was upregulated and activated in EGFR-mutated cells. Mutant EGFR preferentially bound to and tyrosine phosphorylated β-catenin, leading to an increase in β-catenin-mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice. These data suggest that β-catenin plays an essential role in lung tumorigenesis and that targeting the β-catenin pathway may provide novel strategies to prevent lung cancer development or overcome resistance to EGFR TKIs.
Insights
Beta-catenin is crucial for EGFR-mutated lung cancer development and resistance to EGFR tyrosine kinase inhibitors (TKIs). Targeting beta-catenin may offer new strategies for lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have transformed lung cancer treatment.
- Therapeutic resistance to EGFR TKIs is a significant clinical challenge, limiting long-term patient outcomes.
- The underlying mechanisms of TKI resistance and lung tumorigenesis in EGFR-mutated cancers require further elucidation.
Purpose of the Study:
- To investigate the role of beta-catenin in the development and progression of EGFR-mutated lung cancers.
- To explore the potential of targeting the beta-catenin pathway as a therapeutic strategy for overcoming TKI resistance.
Main Methods:
- Analysis of beta-catenin expression and activation in EGFR-mutated lung cancer cells.
- Investigation of the interaction between mutant EGFR and beta-catenin, including tyrosine phosphorylation.
- Assessment of beta-catenin's role in transactivation and its impact on TKI resistance.
- Pharmacological inhibition and genetic deletion of beta-catenin in preclinical lung cancer models.
Main Results:
- Beta-catenin was found to be upregulated and activated in EGFR-mutated lung cancer cells.
- Mutant EGFR directly interacted with and tyrosine phosphorylated beta-catenin, enhancing its activity.
- This interaction was particularly pronounced in cells with the T790M resistance mutation.
- Inhibition or deletion of beta-catenin significantly suppressed tumor growth and formation in EGFR-mutated lung cancer models, including those resistant to TKIs.
Conclusions:
- Beta-catenin is a key mediator in EGFR-mutated lung tumorigenesis.
- The beta-catenin pathway is essential for the development of resistance to EGFR TKIs.
- Targeting beta-catenin represents a promising therapeutic avenue for treating EGFR-mutated lung cancer and overcoming TKI resistance.
Related Concept Videos
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Canonical Wnt Signaling Pathway
Mitogens and the Cell Cycle
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

